Overview

Definition:
-Long QT syndrome (LQTS) is a disorder of cardiac repolarization characterized by a prolonged QT interval on the electrocardiogram, predisposing individuals to potentially life-threatening ventricular arrhythmias, specifically torsades de pointes (TdP)
-It can be congenital (genetic) or acquired.
Epidemiology:
-Congenital LQTS (cLQTS) affects approximately 1 in 2,000 to 1 in 5,000 individuals
-The incidence of acquired LQTS is higher, largely driven by drug-induced QT prolongation
-It is a significant cause of sudden cardiac death (SCD) in young, otherwise healthy individuals
-Certain genetic subtypes are more prevalent in specific populations.
Clinical Significance:
-LQTS represents a critical medical condition in pediatrics due to its association with syncope, seizures, and sudden cardiac death
-Early diagnosis, appropriate risk stratification, and timely management, including the judicious use of beta-blockers and careful sports counseling, are paramount to preventing adverse events and improving long-term outcomes for affected children.

Clinical Presentation

Symptoms:
-Syncope, often triggered by exercise, emotional stress, or auditory stimuli
-Seizures, which may be mistaken for epilepsy
-Palpitations
-Presyncope
-Sudden cardiac arrest (rarely the first presentation)
-Asymptomatic individuals with a prolonged QT interval identified incidentally.
Signs:
-A prolonged corrected QT interval (QTc) on ECG, typically >460 ms in males and >480 ms in females, though thresholds can vary
-Bradycardia, especially during sleep
-Other findings may be non-specific or related to the underlying cause of acquired LQTS.
Diagnostic Criteria:
-The clinical diagnosis of LQTS is based on a combination of ECG findings (QTc duration, T-wave morphology, presence of U waves), clinical history (syncope, SCD in relatives), and genetic testing
-The Schwartz score or similar risk stratification tools are often used
-For example, a QTc > 480 ms with syncope scores highly
-Genetic testing confirms specific gene mutations in cLQTS.

Diagnostic Approach

History Taking:
-Detailed family history of syncope, arrhythmias, SCD, or unexplained deaths at a young age
-Personal history of syncope, near-drowning, or seizures, noting triggers (exercise, emotion, sleep, auditory)
-Medications and electrolyte status in suspected acquired LQTS
-History of hearing loss in Jervell and Lange-Nielsen syndrome.
Physical Examination:
-General physical examination focusing on neurological status and signs of underlying conditions
-Auscultation for murmurs
-Assess for congenital anomalies
-A resting 12-lead ECG is crucial for measuring the QT interval and assessing T-wave morphology
-Holter monitoring can capture intermittent arrhythmias.
Investigations:
-Resting 12-lead ECG: measure QTc, evaluate T-wave morphology (e.g., broad biphasic T waves in LQTS1, flattened T waves in LQTS2)
-Stress testing (with caution and appropriate monitoring): can unmask QT prolongation or provoke arrhythmias
-Holter monitoring: assess for arrhythmias and QT variability
-Echocardiography: to rule out structural heart disease
-Genetic testing: for specific LQTS-associated genes (KCNQ1, KCNH2, SCN5A, etc.) in suspected cLQTS
-Serum electrolytes (potassium, magnesium, calcium) to rule out acquired causes.

Management

Initial Management:
-For acquired LQTS, identify and discontinue offending agents (drugs, electrolyte imbalances)
-Correct electrolyte abnormalities
-Immediate risk stratification for symptomatic patients
-In cases of torsades de pointes with hemodynamic compromise, defibrillation is indicated.
Medical Management:
-Beta-blockers (e.g., propranolol, nadolol) are the cornerstone of therapy for symptomatic cLQTS, particularly LQTS1 and LQTS2
-Dosing is weight-based and titrated to reduce symptoms and arrhythmia burden
-For LQTS3, sodium channel blockers may be considered in select cases
-Magnesium infusion can be used acutely for TdP.
Surgical Management:
-Implantable cardioverter-defibrillator (ICD) implantation is indicated for high-risk patients with cLQTS, including those with a history of syncope despite beta-blocker therapy, aborted SCD, or very prolonged QTc
-Left cardiac sympathetic denervation (LCSD) is an adjunct therapy for refractory cases or intolerance to beta-blockers.
Supportive Care:
-Patient and family education regarding triggers, adherence to medication, and emergency protocols
-Regular follow-up with a pediatric cardiologist specializing in arrhythmias
-Genetic counseling for affected families
-Monitoring for drug interactions and side effects of beta-blockers.

Sports Counseling

Risk Assessment:
-Sports participation for individuals with LQTS requires a careful, individualized risk assessment
-Factors include LQTS genotype, severity of QT prolongation, presence and frequency of symptoms, family history, and response to therapy
-The risk of exercise-induced arrhythmias is genotype-dependent.
Recommendations By Genotype:
-LQTS1: High risk during exertion and with emotional stress
-Generally, participation in low-intensity sports may be considered with strict adherence to beta-blocker therapy and ECG monitoring
-High-intensity competitive sports are usually contraindicated
-LQTS2: Similar risks to LQTS1, particularly with auditory stimuli and exertion
-LQTS3: Lower risk during exertion, but higher risk during sleep/rest
-Beta-blockers are less effective, and ICD may be more commonly indicated
-Competitive sports often restricted.
General Guidelines:
-Participation in organized competitive sports is often restricted or requires careful consideration and close medical supervision
-If cleared, patients must remain on optimal beta-blocker therapy, avoid dehydration and electrolyte imbalances, and be educated about recognizing and responding to symptoms
-Regular ECG monitoring and stress testing (under supervision) are essential
-Absence of symptoms on optimal therapy for a prolonged period is a prerequisite for considering clearance.

Complications

Early Complications:
-Torsades de pointes, leading to syncope or sudden cardiac arrest
-Drug side effects from beta-blockers (bradycardia, hypotension, bronchospasm, fatigue)..
Late Complications:
-Recurrent syncope or seizures despite treatment
-Device-related complications if an ICD is implanted (infection, lead malfunction)
-Ineffective or poorly tolerated medical therapy leading to persistent risk
-Sudden cardiac death.
Prevention Strategies:
-Strict adherence to beta-blocker therapy
-Avoiding known triggers (certain medications, electrolyte imbalances, intense exercise in susceptible genotypes)
-Early identification and management of symptomatic individuals
-Appropriate use of ICD in high-risk patients
-Genetic screening of at-risk family members.

Prognosis

Factors Affecting Prognosis:
-Genotype of LQTS (e.g., LQTS3 generally has a worse prognosis)
-Presence and severity of symptoms (syncope, aborted SCD)
-Family history of SCD
-Response to beta-blocker therapy
-Adherence to medical recommendations
-Effective ICD function if implanted.
Outcomes:
-With appropriate management, including beta-blockers and judicious use of ICDs, the prognosis for individuals with LQTS can be significantly improved, with a marked reduction in the risk of SCD
-However, some individuals may still experience breakthrough events or have a less favorable outcome depending on the factors above.
Follow Up:
-Lifelong follow-up with a pediatric cardiologist specializing in arrhythmias is essential
-This includes regular clinical assessments, ECG monitoring, Holter monitoring, and possibly serial stress testing
-Monitoring for medication adherence and side effects is crucial
-Genetic counseling and cascade screening of family members are important components of long-term management.

Key Points

Exam Focus:
-Recognize LQTS on ECG (prolonged QTc)
-Differentiate congenital vs
-acquired LQTS
-Understand the role of beta-blockers (especially propranolol/nadolol) in cLQTS management
-Differentiate management based on LQTS genotype (e.g., exercise trigger in LQTS1 vs
-rest trigger in LQTS3)
-Indications for ICD and LCSD
-Crucial aspects of sports counseling.
Clinical Pearls:
-Always check electrolytes (K, Mg, Ca) and review medications in patients with a prolonged QT interval
-Family history is critical for diagnosing cLQTS
-Syncope in a young person, especially with exercise or an auditory trigger, should raise suspicion for LQTS
-Beta-blockers are prophylactic, not acutely corrective for TdP.
Common Mistakes:
-Mistaking LQTS for epilepsy or vasovagal syncope
-Neglecting family history
-Inadequate follow-up and monitoring
-Prescribing beta-blockers without proper risk stratification and ongoing assessment
-Failing to counsel comprehensively on sports participation based on genotype and risk.